SPT-348 is a serotonin receptor modulator and non-hallucinogenic psychoplastogen of the lysergamide family which is under development for the treatment of depression, anxiety, and other neuropsychiatric disorders. It is a prodrug of 2-bromo-LSD (bromolysergide; BOL-148), a non-selective serotonin receptor modulator and partial agonist of the serotonin 5-HT2A receptor, and is an analogue of the serotonergic psychedelic LSD. The drug is said to employ a novel formulation involving a triglyceride linker that helps it to bypass first-pass metabolism in the liver that is said to be prominent with LSD. As of 2025, SPT-348 is in the discovery or preclinical research stage of development.
See also List of investigational hallucinogens and entactogens Non-hallucinogenic 5-HT2A receptor agonist JRT Lisuride
References
External links Our Pipeline - Seaport Therapeutics